Abstracts tagged "rheumatoid arthritis (RA) and safety"

Abstract Number: 511 • 2017 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, David Hyslop⁴, William L. Macias⁴, Terence P. Rooney⁴, Lei Chen⁴, Christina L. Dickson⁴, Jennifer Riddle Camp⁴, Tracy Cardillo⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved in the EU for the treatment of moderately…
Abstract Number: 540 • 2017 ACR/ARHP Annual Meeting
Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Nobunori Takahashi, Toshihisa Kojima, Shuji Asai, Tatsuo Watanabe, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue and Naoki Ishiguro, Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 1100 • 2017 ACR/ARHP Annual Meeting
Communication between Inpatient and Outpatient Specialty Clinicians: Developing a Better Understanding of Patients with Rheumatoid Arthritis Who Are Admitted to the Hospital
Abraham Tacang¹, Christina Downey², Alfred Denio¹, Eric Newman³ and Lisa L. Schroeder⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Department of Rheumatology, Geisinger Medical Center, Danville, PA, ⁴Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatoid arthritis (RA). Communication between clinicians becomes even more crucial when a patient…
Abstract Number: 1909 • 2017 ACR/ARHP Annual Meeting
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Mark C. Genovese¹, Arthur Kavanaugh², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁵, Xiao Ding¹⁵, Pille Harrison¹⁶, Annegret Van der Aa¹⁶, René Westhovens¹⁷ and Rieke Alten¹⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of California, San Diego, La Jolla, CA, ³Oregon Health Sciences University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Vinnitsa Regional Clinical Hospital, Vinnitsa, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Rendelo, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³QUALICLINIC Kft., Budapest, Hungary, ¹⁴Centrum Medyczne AMED Warszawa Targówek, Warszawa, Poland, ¹⁵Gilead Sciences, Inc, Foster City, CA, ¹⁶Galapagos NV, Mechelen, Belgium, ¹⁷KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹⁸Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) currently in Phase 3 development for the treatment of rheumatoid arthritis (RA).…
Abstract Number: 2455 • 2017 ACR/ARHP Annual Meeting
Efficacy of Etanercept in Elderly Patients with Rheumatoid Arthritis
Christopher J. Edwards¹, Katherine Roshak², Jack F Bukowski³, Ronald Pedersen⁴, Mazhar Thakur⁵, Lisa Marshall² and Heather Jones², ¹University Hospital Southampton, Southampton, United Kingdom, ²Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ³Clinical Affairs, Pfizer, Collegeville, PA, ⁴Department of Biostatistics, Pfizer, Collegeville, PA, ⁵Pfizer Ltd, Sandwich, United Kingdom
Background/Purpose: Ageing is associated with declining immune cell function and age-related comorbidities.1,2 In the US, the prevalence of rheumatoid arthritis (RA) is ~2% in individuals…
Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting
Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis
Mayumi Matsuda¹, Yu Funakubo Asanuma², Noritsune Kouzu³ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Saitama Medical University, Moroyama, Japan
Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
Abstract Number: 1605 • 2016 ACR/ARHP Annual Meeting
Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Roy Fleischmann¹, Mark C. Genovese², Janet van Adelsberg³, Erin Mangan⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶ and TWJ Huizinga⁷, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab (150 or 200 mg every 2 weeks [q2w] subcutaneously) + MTX demonstrated efficacy vs placebo…
Abstract Number: 1622 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Iguratimod in Patients with Active Rheumatoid Arthritis: A Multicenter, Single-Arm, Open-Label, Real World Study
Rong Mu, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To evaluate the safety and efficacy of iguratimod, a novel DMARD, in active rheumatoid arthritis patients. Methods: Patients with active rheumatoid arthritis received iguratimod…
Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Leslie R. Harrold^1,2, Heather J. Litman¹, Katherine C. Saunders¹, Kimberly J. Dandreo¹, Bernice Gershenson², Jeffrey D. Greenberg^1,3, Robert Low⁴, Jeffrey Stark⁴, Robert Suruki⁴, Srihari Jaganathan⁴ and Mohamed Yassine⁴, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³NYU School of Medicine, New York, NY, ⁴UCB Pharma, Smyrna, GA
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
Abstract Number: 2623 • 2016 ACR/ARHP Annual Meeting
Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase 1, Proof-of-Concept Clinical Trial
Dong Jin Go¹, Hee-suk Lim², Ahrmi Cho³, Kyounghwan Roh³, Kwang-Won Seo³, Kyung-Sun Kang^3,4 and Kichul Shin⁵, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea, ³Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, Korea, The Republic of, ⁴Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Korea, The Republic of, ⁵Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Background/Purpose: The immunomodulatory actions of human umbilical cord blood (hUCB)-derived mesenchymal stem cells (MSCs) in rheumatoid arthritis (RA) have been studied extensively via in vitro…
Abstract Number: 2641 • 2016 ACR/ARHP Annual Meeting
Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA
Sofia Ramiro¹, Alexandre Sepriano¹, Katerina Chatzidionysiou², Jackie L. Nam³, Josef Smolen⁴, Désirée van der Heijde⁵, Maxime Dougados⁶, Ronald van Vollenhoven⁷, Johannes WJ Bijlsma⁸, GR Burmester⁹, Marieke Scholte-Voshaar¹⁰ and RBM Landewé¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Paris Descartes University, Paris, France, ⁷Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité – University Medicine Berlin, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Medical Center, Amsterdam, Netherlands
Background/Purpose: As part of the update of the EULAR recommendations for the management of RA, we performed a systematic literature review to assess the safety…
Abstract Number: 3238 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Adrian Richter¹, Anja Strangfeld², Prof. Dr. Matthias Schneider³, Thomas Klopsch⁴, Andreas Kapelle⁵, Jörg Kaufmann⁶, Angela Zink⁷ and Joachim Listing⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁴Rheumatologist in private practice, Neubrandenburg, Germany, ⁵Rheumatologist, Hoyerswerda, Germany, ⁶Medical practice specialising, Ludwigsfelde, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Tumor-necrosis-factor-α inhibition (TNFi) was assumed to be a relevant mechanism for the treatment of sepsis[1]. However, randomized controlled trials failed to show a survival…
Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike¹⁵, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc., Japan, Tokyo, Japan, ¹³University Hospital, Maastricht, Netherlands, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…
Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Hjalmar Wadström¹, Johan Askling² and the ARTIS study group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…
Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Rafat Faraawi¹, Raman Joshi², William G Bensen³, Denis Choquette⁴, Wojciech Olsynzynski⁵, Regan Arendse⁵, Maqbool Sheriff⁶, Proton Rahman⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, Cathy Tkaczyk¹¹ and Brendan Osborne¹¹, ¹McMaster University, Hamilton, ON, Canada, ²William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, ON, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Medicine, Memorial University, St John's, NF, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].